1
|
Gaudio M, Jacobs F, Benvenuti C, Saltalamacchia G, Gerosa R, De Sanctis R, Santoro A, Zambelli A. Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer. Breast Cancer Res Treat 2024; 203:487-495. [PMID: 37923964 DOI: 10.1007/s10549-023-07151-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 09/29/2023] [Indexed: 11/06/2023]
Abstract
PURPOSE HER2-low breast cancer (BC) is a novel entity with relevant therapeutic implications, especially in hormone receptor (HR) positive BC. This study examines whether HER2 mRNA through the 21-gene assay, Oncotype DX (ODX), can refine the diagnosis of HER2-low and HER2-zero, obtained by immunohistochemistry (IHC). METHODS Between Jan 2021 and Jan 2023, 229 consecutive HR-positive HER2-negative early BC (T1-3 N0-1) have been characterised by IHC and ODX. HER2 status by IHC was either zero (IHC-0) or low (IHC-1 + and IHC-2 + /ISH-negative) while HER2-zero was further divided into HER2-null (IHC-0) and HER2-ultralow (IHC-1-10%). HER2 gene expression by ODX was negative if lower 10.7. RESULTS The distribution of HER2 IHC was as follows: 53.3% HER2-0, 29.25% HER2-1 + , and 17.5% HER2-2 + . The clinicopathological characteristics were similar in the three groups, with higher PgR-negative rate in HER2-zero (13.9% vs 3% vs 5%). The distribution of RS was homogeneous in the three groups with the median HER2 gene expression of 9.20 [IQR: 8.70-9.60]. HER2 gene expression gradually increased as the IHC score, with substantial overlap. After adjusting for confounders, HER2-1 + and HER2 2 + had a significant positive correlation between HER2 gene expression and IHC [OR 1.42, 95% CI 1.21 to 1.68, p < 0.001; OR 1.96, 95% CI 1.61 to 2.37, p < 0.001] compared to the HER2-zero group. HER2 gene expression did not differ between HER2-null and HER2-ultralow subgroups. CONCLUSION Due to the substantial overlap, the HER2 gene expression is unable to properly distinguish HER2-low and HER2-zero IHC whose accurate identification is critical in the context of HER2-negative BC.
Collapse
Affiliation(s)
- M Gaudio
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy
| | - F Jacobs
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy
| | - C Benvenuti
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy
| | - G Saltalamacchia
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
| | - R Gerosa
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy
| | - R De Sanctis
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy.
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy.
| | - A Santoro
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy
| | - A Zambelli
- Department of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, MI, Italy
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, 20089, Rozzano, MI, Italy
| |
Collapse
|
2
|
Tiberio P, Antunovic L, Gaudio M, Viganò A, Pastore M, Miggiano C, Jacobs F, Benvenuti C, Farina E, Chiti A, Santoro A, De Sanctis R. The relationship among bowel FDG-PET uptake, pathological complete response, and eating habits in breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01520-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Miglietta F, Ragazzi M, Fernandes B, Griguolo G, Massa D, Bisagni A, Bottosso M, Porra F, Gaudio M, Iannaccone D, Fassan M, Lo Mele M, Gasparini E, Zarrilli G, Coiro S, Dore L, Zambelli A, Bisagni G, Guarneri V, Dieci M. A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01354-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Tiberio P, Antunovic L, Gaudio M, Viganò A, Pastore M, Miggiano C, Jacobs F, Benvenuti C, Farina E, Chiti A, Santoro A, De Sanctis R. 48P The relationship among bowel FDG-PET uptake, pathological complete response, and the influence of eating and exercise habits in breast cancer patients undergoing neoadjuvant chemotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.09.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
5
|
Aramini B, Masciale V, Samarelli AV, Dubini A, Gaudio M, Stella F, Morandi U, Dominici M, De Biasi S, Gibellini L, Cossarizza A. Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non–small cell lung cancer. Front Immunol 2022; 13:959114. [PMID: 36032082 PMCID: PMC9399732 DOI: 10.3389/fimmu.2022.959114] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 07/18/2022] [Indexed: 12/29/2022] Open
Abstract
Lung cancer is the leading cancer in the world, accounting for 1.2 million of new cases annually, being responsible for 17.8% of all cancer deaths. In particular, non–small cell lung cancer (NSCLC) is involved in approximately 85% of all lung cancers with a high lethality probably due to the asymptomatic evolution, leading patients to be diagnosed when the tumor has already spread to other organs. Despite the introduction of new therapies, which have improved the long-term survival of these patients, this disease is still not well cured and under controlled. Over the past two decades, single-cell technologies allowed to deeply profile both the phenotypic and metabolic aspects of the immune cells infiltrating the TME, thus fostering the identification of predictive biomarkers of prognosis and supporting the development of new therapeutic strategies. In this review, we discuss phenotypic and functional characteristics of the main subsets of tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating myeloid cells (TIMs) that contribute to promote or suppress NSCLC development and progression. We also address two emerging aspects of TIL and TIM biology, i.e., their metabolism, which affects their effector functions, proliferation, and differentiation, and their capacity to interact with cancer stem cells.
Collapse
Affiliation(s)
- Beatrice Aramini
- Division of Thoracic Surgery, Department of Experimental, Diagnostic and Specialty Medicine—DIMES of the Alma Mater Studiorum, University of Bologna, G.B. Morgagni—L. Pierantoni Hospital, Forlì, Italy
| | - Valentina Masciale
- Division of Oncology and Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Anna Valeria Samarelli
- Division of Oncology and Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Alessandra Dubini
- Division of Pathology, G.B. Morgagni—L. Pierantoni Hospital, Forlì, Italy
| | - Michele Gaudio
- Division of Pathology, G.B. Morgagni—L. Pierantoni Hospital, Forlì, Italy
| | - Franco Stella
- Division of Thoracic Surgery, Department of Experimental, Diagnostic and Specialty Medicine—DIMES of the Alma Mater Studiorum, University of Bologna, G.B. Morgagni—L. Pierantoni Hospital, Forlì, Italy
| | - Uliano Morandi
- Division of Thoracic Surgery, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Massimo Dominici
- Division of Oncology and Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Sara De Biasi
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
| | - Lara Gibellini
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
| | - Andrea Cossarizza
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
- National Institute for Cardiovascular Research, Bologna, Italy
- *Correspondence: Andrea Cossarizza,
| |
Collapse
|
6
|
De Sanctis R, Antunovic L, Benvenuti C, Jacobs F, Gaudio M, Ilieva M, Viganò A, Chiti A, Santoro A. 50P Brain 18-FDG-PET patterns in early breast cancer subtypes: Relationship with headache. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Ambrosini-Spaltro A, Limarzi F, Gaudio M, Calpona S, Meccariello G. PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. Virchows Arch 2022; 481:93-99. [PMID: 35420378 DOI: 10.1007/s00428-022-03322-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 02/13/2022] [Accepted: 04/05/2022] [Indexed: 12/22/2022]
Abstract
Immune checkpoint inhibitors have recently been approved for the treatment of advanced head and neck squamous cell carcinoma (HNSCC). The determination of PD-L1 using the combined positive score (CPS) is of utmost importance in the selection of patients. However, it is unclear which material should be examined. This study aimed to compare PD-L1 CPS in the resections of primary tumors and metastatic lymph nodes, and in the biopsies of the primary tumors.We collected 30 resected HNSCCs with lymph node metastases; in 17 of these, preoperative biopsies were retrieved. PD-L1 immunostaining of 75 samples was performed using the Dako 22C3 antibody on the Ventana ULTRA platform. An appropriate internal control was performed on each slide. CPS was calculated for each reaction. Concordance values and k were calculated for each patient. CPS cut-off values were fixed at 0 and 20.Tumors were resected from the oral cavity (4), oropharynx (17), hypopharynx (1), and larynx (8). The overall concordance of CPS between tumor resection and lymph node metastasis was 76.7% (k = 0.593). The overall concordance of CPS between tumor resection and tumor biopsy was 86.7% (k = 0.688). The agreement was moderate to substantial for each comparison.PD-L1 CPS may be correctly determined not only in resected primary tumors, but also in removed lymph node metastases, as well as in preoperative biopsies.
Collapse
Affiliation(s)
- Andrea Ambrosini-Spaltro
- Pathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Carlo Forlanini, 34, 47121, Forlì, Italy.
| | - Francesco Limarzi
- Pathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Carlo Forlanini, 34, 47121, Forlì, Italy
| | - Michele Gaudio
- Pathology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Carlo Forlanini, 34, 47121, Forlì, Italy
| | - Sebastiano Calpona
- Clinical and Experimental Oncology of Immunotherapy and Rare Cancers, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - Giuseppe Meccariello
- Otolaryngology and Head-Neck Surgery Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy
| |
Collapse
|
8
|
Rossi T, Gallerani G, Angeli D, Cocchi C, Bandini E, Fici P, Gaudio M, Martinelli G, Rocca A, Maltoni R, Fabbri F. Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. Cancers (Basel) 2020; 12:cancers12092490. [PMID: 32887501 PMCID: PMC7565733 DOI: 10.3390/cancers12092490] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 08/28/2020] [Accepted: 08/31/2020] [Indexed: 12/18/2022] Open
Abstract
Simple Summary Circulating tumor cells (CTCs) are crucial for the identification of patients with a higher risk of relapse, including those diagnosed with breast cancer (BC). The aim of this study was to explore their molecular aspects in 11 early-stage BC patients during patient management, focusing on copy number alterations (CNAs) and exploiting a single-CTC next-generation sequencing approach. CTCs showed different degrees of aberration based on access time. Moreover, CTCs, in particular those persisting even months after tumor resection, shared CNAs with matched tumor tissue. Enrichment analyses of CNAs on CTCs highlighted peculiar aberrations, especially associated with interferon (IFN)-associated terms. The study of CTCs CNAs can provide information about the molecular mechanisms involving CTC-related processes and their survival ability in occult niches, supporting the goal of exploiting their application in patients’ surveillance and follow-up. Abstract Circulating tumor cells (CTCs) are a rare population of cells representing a key player in the metastatic cascade. They are recognized as a validated tool for the identification of patients with a higher risk of relapse, including those diagnosed with breast cancer (BC). However, CTCs are characterized by high levels of heterogeneity that also involve copy number alterations (CNAs), structural variations associated with gene dosage changes. In this study, single CTCs were isolated from the peripheral blood of 11 early-stage BC patients at different time points. A label-free enrichment of CTCs was performed using OncoQuick, and single CTCs were isolated using DEPArray. Libraries were prepared from single CTCs and DNA extracted from matched tumor tissues for a whole-genome low-coverage next-generation sequencing (NGS) analysis using the Ion Torrent S5 System. The analysis of the CNA burden highlighted that CTCs had different degrees of aberration based on the time point and subtype. CTCs were found even six months after surgery and shared CNAs with matched tumor tissue. Tumor-associated CNAs that were recurrent in CTCs were patient-specific, and some alterations involved regions associated with BC and survival (i.e., gains at 1q21-23 and 5p15.33). The enrichment analysis emphasized the involvement of aberrations of terms, associated in particular with interferon (IFN) signaling. Collectively, our findings reveal that these aberrations may contribute to understanding the molecular mechanisms involving CTC-related processes and their survival ability in occult niches, supporting the goal of exploiting their application in patients’ surveillance and follow-up.
Collapse
Affiliation(s)
- Tania Rossi
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (G.G.); (C.C.); (E.B.); (P.F.); (F.F.)
- Correspondence: ; Tel.: +39-05-4373-9982
| | - Giulia Gallerani
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (G.G.); (C.C.); (E.B.); (P.F.); (F.F.)
| | - Davide Angeli
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy;
| | - Claudia Cocchi
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (G.G.); (C.C.); (E.B.); (P.F.); (F.F.)
| | - Erika Bandini
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (G.G.); (C.C.); (E.B.); (P.F.); (F.F.)
| | - Pietro Fici
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (G.G.); (C.C.); (E.B.); (P.F.); (F.F.)
| | - Michele Gaudio
- Pathology Unit, AUSL Romagna, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy;
| | - Giovanni Martinelli
- Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy;
| | - Andrea Rocca
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (A.R.); (R.M.)
| | - Roberta Maltoni
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (A.R.); (R.M.)
| | - Francesco Fabbri
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; (G.G.); (C.C.); (E.B.); (P.F.); (F.F.)
| |
Collapse
|
9
|
Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D. Multidisciplinary Approach to the Treatment of Bone Metastases: Osteo-Oncology Center, a New Organizational Model. Tumori 2018; 95:291-7. [DOI: 10.1177/030089160909500304] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background Bone metastases are responsible for high morbidity in cancer patients. The frequency of pain and other serious complications associated with such metastases depends on the site and type of lesions and preventive therapy. The present paper aims to inform the scientific community about a new organizational health care model specifically designed for patients with bone metastases, in the hope of stimulating the creation of similar initiatives whose goals are to decrease the high morbidity of this pathology, reduce the frequency of complications, limit psychophysical distress of patients, and improve quality of life. Methods In January 2005, an Osteo-Oncology Center was opened in our institute to provide multidisciplinary care (19 specialists involved) for patients with bone metastases, to train physicians, and to conduct research in the field. Results In its first three years of activity, 601 multidisciplinary team consultations were made and a total of 425 patients were seen. The most frequent primary tumor site was the lung in males and the breast in females. Upon presentation at the Center, 79% of patients reported experiencing a level of pain (median pain intensity, 3.69) that interfered with normal daily activities. An anonymous questionnaire was also completed on the quality of the service provided: 75% of patients were very satisfied, 23% were satisfied, 1% responded “I don't know”, and only 1% expressed dissatisfaction. Conclusions Our preliminary results confirm the usefulness of a multidisciplinary center for the management of patients with bone metastases, especially in terms of decreasing psychophysical suffering.
Collapse
Affiliation(s)
- Toni Ibrahim
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Emanuela Flamini
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Laura Fabbri
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Patrizia Serra
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Laura Mercatali
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Rossana Ricci
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Emanuele Sacanna
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Maria Cristina Falasconi
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Roberto Casadei
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Riccardo Galassi
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Massimo Giannini
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Oscar Bazzocchi
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Filippo Calzolari
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Roberta Nunziatini
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Michele Gaudio
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Marco Maltoni
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| | - Dino Amadori
- Osteo-Oncology Center, Istituto Romagnolo Scientifico per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
| |
Collapse
|
10
|
Paradiso A, Marubini E, Verderio P, Cortese M, Pizzamiglio S, De Paola F, Silvestrini R, Simone G, Sarotto I, Carcangiu M, Menard S, Tagliabue E, Mottolese M, Benevolo M, Bisceglia M, Giardina E, Maiorano E, Napoli A, Querzoli P, Nenci I, Pedriali M, Rinaldi R, Bianchi S, Vezzosi V, Collecchi P, Bevilacqua G, Colombari R, Caneva A, Gasparin P, Rucca V, Morigi F, De Paola F, Dubini A, Gaudio M, Medri L, Padovani F, Saragoni L, Volpi A, Granato A, Marinaro E, Folicaldi S, Ghidoni D, Cortecchia S, Veronese S, Galli C, Gambacorta M, Stella M, Rizzo A, Nizzoli R, Bozzetti C, Guazzi A, Naldi N, Sidoni A, Bucciarelli E, Ludovini V, Pistola L, Bernardi L, Ghisolfi G, Pecchioni C, Sapino A, Bussolati G, Barbareschi M, Dalla Palma P, Leonardi E. Interobserver Reproducibility of Immunohistochemical Her-2/Neu Assessment in Human Breast Cancer: An Update from INQAT round III. Int J Biol Markers 2018. [DOI: 10.1177/172460080502000307] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The clinical interest in HER-2/neu is related to trastuzumab, a drug used to treat patients with invasive breast carcinoma overexpressing the HER-2/neu protein. It is very important to correctly identify those patients who may benefit from trastuzumab by accurate assessment of the HER-2/neu status. Of the various methods available, the Dako Herceptest for immunohistochemical assay is considered the most reliable to reach this goal. The aim of this study was to investigate within a group of Italian laboratories the reproducibility of the results of HER-2/neu assessment by means of the Dako scoring system on slides stained with the Herceptest kit. This study was also conceived as the continuation of one of our previous studies, which was similar in its aims but different in the classification criteria adopted. Our results show that, whereas the intra-observer reproducibility was generally satisfactory, the interobserver reproducibility was not. Moreover, our findings confirm that the two extreme classes (0 and 3+) are more easy to identify than the other two and that the Herceptest does not allow to discriminate optimally between scoring classes 2+ and 3+. These findings are relevant in clinical practice where the treatment choice is based on categories defined by this assay, suggesting the need of adopting educational programs and/or new reference materials to improve the assay performance.
Collapse
Affiliation(s)
| | | | | | - P. Verderio
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - M.E. Cortese
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - S. Pizzamiglio
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | | | - R. Silvestrini
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | | | | | - M.L. Carcangiu
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - S. Menard
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - E. Tagliabue
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | - M. Mottolese
- Istituto Regina Elena per lo Studio e la Cura dei Tumori, Rome
| | - M. Benevolo
- Istituto Regina Elena per lo Studio e la Cura dei Tumori, Rome
| | - M. Bisceglia
- IRCCS - Ospedale Casa Sollievo della Sof-ferenza, San Giovanni Rotondo
| | - E. Giardina
- Azienda Os-pedaliera e Università degli Studi di Bari, Bari
| | - E. Maiorano
- Azienda Os-pedaliera e Università degli Studi di Bari, Bari
| | - A. Napoli
- Azienda Os-pedaliera e Università degli Studi di Bari, Bari
| | | | - I. Nenci
- Università degli Studi di Ferrara, Ferrara
| | | | - R. Rinaldi
- Università degli Studi di Ferrara, Ferrara
| | - S. Bianchi
- Azienda Ospedaliera Careggi e Università degli Studi di Firenze, Florence
| | - V. Vezzosi
- Azienda Ospedaliera Careggi e Università degli Studi di Firenze, Florence
| | | | | | | | | | | | - V. Rucca
- Os-pedale Cazzavillan, Arzignano
| | | | - F. De Paola
- U.O. Anatomia Patologica Ospedale Mor-gagni-Pierantoni, Forlì
| | - A. Dubini
- U.O. Anatomia Patologica Ospedale Mor-gagni-Pierantoni, Forlì
| | - M. Gaudio
- U.O. Anatomia Patologica Ospedale Mor-gagni-Pierantoni, Forlì
| | - L. Medri
- U.O. Anatomia Patologica Ospedale Mor-gagni-Pierantoni, Forlì
| | - F. Padovani
- U.O. Anatomia Patologica Ospedale Mor-gagni-Pierantoni, Forlì
| | - L. Saragoni
- U.O. Anatomia Patologica Ospedale Mor-gagni-Pierantoni, Forlì
| | - A. Volpi
- U.O. Oncologia Medica, Os-pedale Morgagni-Pierantoni, Forlì
| | - A.M. Granato
- U.O. Oncologia Medica, Os-pedale Morgagni-Pierantoni, Forlì
| | | | | | | | | | | | - C. Galli
- Azienda Os-pedaliera Niguarda, Milan
| | | | | | | | | | | | | | | | - A. Sidoni
- Anatomia Patologica, Azienda Ospedaliera Policlinico Monteluce, Perugia
| | - E. Bucciarelli
- Anatomia Patologica, Azienda Ospedaliera Policlinico Monteluce, Perugia
| | - V. Ludovini
- Oncologia Medica, Azienda Os-pedaliera Policlinico Monteluce, Perugia
| | - L. Pistola
- Oncologia Medica, Azienda Os-pedaliera Policlinico Monteluce, Perugia
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Brooks SC, Scales D, Dainty K, Gray S, Pinto R, Racz E, Gaudio M, Amaral A, Baker A, Chapman M, Crystal E, Dorian P, Fam N, Fowler R, Friedrich J, Madan M, Rubenfeld G, Smith O, Morrison LJ. Post Arrest Consult Team: a knowledge translation strategy for post-cardiac arrest care. Crit Care 2014. [PMCID: PMC4069509 DOI: 10.1186/cc13682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
12
|
Ricci M, Buci L, Gaudio M, Milandri C. Thyroid metastases from clear cell renal cell carcinoma: A case report. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D. The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study. Oncology 2011; 80:225-31. [DOI: 10.1159/000327585] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Accepted: 01/24/2011] [Indexed: 12/20/2022]
|
14
|
Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Ricci R, Scarpi E, Serra P, Fabbri F, Serra L, Amadori D. Abstract P1-13-04: Immunohistochemical Evaluation of RANK/RANKL/OPG Axis and CXCR4 in Primary Breast Cancer and Their Role in Bone Metastasization. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-13-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The RANK/RANKL/OPG axis plays an important role in the bone metastasization process. CXCL12 is overexpressed in bone and, like its receptor, CXCR4, is a determinant of organ tropism. The objective of the present study was to evaluate whether the expression of these markers in primary breast cancer can predict the onset of bone metastases. Methods: Marker expression was evaluated by immunohistochemical staining in paraffin-embedded sections of primary breast cancers from 40 individuals: 10 patients (median age 64 years, range 48-78) showed no evidence of disease (NED — control group) at a median of 9.8 (range 6.9-11.5) years, while 30 (median age 67 years, range 42-87) had relapsed. In the latter group, 10 (median age 66 years, range 42-87) had visceral metastases (VM — control group) and 20 (median age 69 years, range 42-87) had bone metastases (BM — case group), both confirmed radiologically. The 3 patient subgroups (NED, visceral lesions, bone lesions) were matched for age classes (≥60 years, > 60 years). The study design was reviewed and approved by the local ethics committee.
Results: In the overall series, 17.5% of tumors were positive for RANK, 22.5% for OPG and 25% for CXCR4. None of the patients expressed RANKL. RANK and OPG resulted equally expressed in 20% of NED patients, while CXCR4 was expressed in only 10% of this group. OPG was expressed in 20% of VM patients, whereas RANK or CXCR4 were not detected. RANK and OPG positivity was present in 25% of BM patients, while CXCR4 was expressed in 45% of cases. CXCR4 was the only marker with a significantly higher frequency of expression in bone metastases than in visceral lesions (p=0.013). Taking into consideration all the patients without bone involvement (NED plus VM patients), it was observed that CXCR4 expression, alone and in combination with RANK, significantly discriminated between BM patients and the control group (p=0.008 and P<0.001, respectively). ER-positivity and HER2-negative status were observed in 80% and 95% of BM patients, respectively, but neither discriminated between cases and controls. Conclusions: In our study, ER-positivity and HER2- negativity identified a high percentage of bone relapse patients, but also highlighted patients who did not have bone involvement. RANK and CXCR4 expression, on the other hand, would appear to be a more accurate predictor of bone relapse. Such evidence could help to identify patients with a high probability of developing bone metastases, which can be treated with bisphosphonates or other bone-targeted therapies, such as denosumab, in an attempt to prevent distant metastases. Our results are currently being validated in a larger series of breast cancer patients.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-13-04.
Collapse
Affiliation(s)
- T Ibrahim
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - E Sacanna
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - M Gaudio
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - L Mercatali
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - R Ricci
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - E Scarpi
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - P Serra
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - F Fabbri
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - L Serra
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| | - D. Amadori
- Osteoncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
| |
Collapse
|
15
|
Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Ricci R, Scarpi E, Serra P, Fabbri F, Serra L, Amadori D. Accuracy of RANK/OPG and CXCR4 compared to hormone receptors in predicting bone metastases in patients with breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Ricci R, Scarpi E, Ricci M, Serra P, Serra L, Arienti C, Bravaccini S, Amadori D. Abstract 2241: Role of tissue markers in the prediction of bone metastases from breast cancer. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-2241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Bone metastasis is a frequent event in patients with breast cancer. OPG (osteoprotegerin) protects bone from excessive resorption by binding to RANK-L (receptor activator of nuclear factor-kB-ligand) and by preventing it from binding to RANK. These molecules are closely involved in the process of metastasization to bone. CXCL12/SDF-1α, the ligand of CXCR4, is overexpressed in bone, and the local chemokine milieu is now emerging as a key determinant in organ selectivity by tumor cells. We carried out a retrospective analysis to evaluate the potential role of these biological markers in predicting bone metastasization in breast cancer patients.
Materials and methods: OPG and CXCR4 expression was determined by avidin-biotin immunohistochemistry using a polyclonal (H-249, Santa Cruz) and monoclonal (Ab58176, Abcam) antibody, respectively. Immunohistochemical staining was carried out on sections from paraffin-embedded blocks of 40 primary breast cancers. Ten patients (median age of 64 years, range 48-78) were disease-free (DF) at a median of 9.8 (range 6.9-11.5) years, while 30 (median age 67 years, range 42-87) had relapsed. In the latter group, 10 (median age 66 years, range 42-87) had visceral metastases (VM) and 20 (median age 69 years, range 42-87) had bone metastases (BM).
Results: Considering only strong cytoplasmic expression as positive, 22.5% of tumors were positive for OPG and 25% for CXCR4. In particular, OPG was expressed in 20% of tumors in DF patients and in 25% in BM patients. Conversely, CXCR4 was expressed in 10% of tumors in DF patients and in 45% in BM patients. OPG was expressed in only 20% of tumors in VM patients. There was no correlation between OPG and CXCR4 expression, and positivity to at least one of the two markers was observed in 30% of tumors in DF patients, 20% in VM patients and 55% in BM patients. In this last subgroup, there were no statistically significant associations between marker expression and tumor characteristics. Furthermore, no relation was observed between marker expression and disease-free or overall survival in BM patients.
Conclusions: Our preliminary results suggest that cytoplasmic CXCR4 expression in primary breast cancers could play a role in predicting bone metastases. Enrolment of breast cancer patients in a larger study is ongoing to confirm these data and to evaluate the predictive role of RANK and RANK-L in bone metastasization.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2241.
Collapse
Affiliation(s)
- Emanuele Sacanna
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Toni Ibrahim
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Michele Gaudio
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Laura Mercatali
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Rossana Ricci
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Emanuela Scarpi
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Marianna Ricci
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Patrizia Serra
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Luigi Serra
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Chiara Arienti
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Sara Bravaccini
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| | - Dino Amadori
- 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy
| |
Collapse
|
17
|
Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Ricci R, Scarpi E, Ricci M, Serra P, Amadori D. PP24 CXCR4: a predictive marker of bone metastases in breast cancer patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72205-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
18
|
Volpi A, Bravaccini S, Medri L, Cerasoli S, Gaudio M, Amadori D. Usefulness of immunological detection of the human telomerase reverse transcriptase. Anal Cell Pathol (Amst) 2005; 27:347-53. [PMID: 16373967 PMCID: PMC4617503 DOI: 10.1155/2005/808343] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE Recent years have seen a considerable wealth of studies conducted on the potential usefulness of telomerase determination in diagnosis, prognosis and targeted cancer therapy. The frequently used Telomeric Repeat Amplification Protocol assay suffers from some drawbacks, the most important being the rate of false positives. In situ analysis using well characterised antibodies directed against the human telomerase reverse transcriptase (hTERT) would therefore appear to be important to morphologically identify the nature of telomerase positive cells. METHODS We performed immunostaining in a series of cultured cells and in normal, preneoplastic and tumour tissues from different organs using a monoclonal antibody directed against the catalytic subunit of telomerase. RESULTS Immunoreactivity was not observed in perennial cells of terminally differentiated cardiac and skeletal muscular tissues or in small pyramidal cells of the cerebral cortex. Conversely, it was found in other normal somatic tissues as well as in precancerous lesions and in all tumour histotypes. CONCLUSIONS Immunohistochemistry with a well characterised hTERT-specific monoclonal antibody permitted the identification of hTERT immunopositive cells in normal somatic tissues. Whether hTERT protein detected by immunostaining with hTERT-specific Tel 3 36-10 antibody is actually the degraded form of the protein that retains hTERT antigenicity but not enzymatic function, or whether it represents the real, potentially functional catalytic subunit of the enzyme, immunohistochemistry would not seem to represent a useful tool to investigate the role of telomerase and the mechanisms involved in its regulation.
Collapse
Affiliation(s)
- Annalisa Volpi
- Division of Oncology, Morgagni-Pierantoni Hospital, Forlì, Italy.
| | | | | | | | | | | |
Collapse
|
19
|
Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, Gaudio M, Frassineti GL, Amadori D, Flamini E. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann Oncol 2005; 17:424-8. [PMID: 16357022 DOI: 10.1093/annonc/mdj109] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The aim of the present study was to evaluate the accuracy of two markers, maspin and mammaglobin B, singly or in combination, to detect breast cancer. To define better the potential and limits of the two markers for diagnostic purposes, blood positivity was analyzed in relation to clinical, pathological and biological tumor characteristics. PATIENTS AND METHODS The markers were determined in peripheral blood (PB) samples from 27 healthy donors and 140 previously untreated patients using nested reverse transcriptase polymerase chain reaction (RT-PCR). RESULTS Positivity for maspin in blood samples was observed in 24% of patients with an 89% specificity. For mammaglobin B, positivity was observed in 7% of patients and never in healthy donors. The presence of maspin was correlated with cell proliferation of the primary tumor (P = 0.015), whereas mammaglobin B positivity correlated with pathological stage (P = 0.013). The presence of either marker was significantly related to nodal status. CONCLUSIONS Our results indicate that the two markers in association could represent a potentially useful non-invasive tool to detect breast cancer. The validation of these markers as indicators of high risk of relapse is ongoing in a series of patients with an adequate follow-up.
Collapse
|
20
|
Barzanti F, Dal Susino M, Volpi A, Amadori D, Riccobon A, Scarpi E, Medri L, Bernardi L, Naldi S, Aldi M, Gaudio M, Zoli W. Comparison between different cell kinetic variables in human breast cancer. Cell Prolif 2001; 33:75-89. [PMID: 10845252 PMCID: PMC6496221 DOI: 10.1046/j.1365-2184.2000.00165.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Cell kinetics holds a prominent role among biological factors in predicting clinical outcome and response to treatment in neoplastic patients. Different cell kinetic variables are often considered as valid alternatives to each other, but the limited size of case series analysed in several studies and the lack of simultaneous determinations of all the variables on the same tumours do not justify this conclusion. In the present study, the correlation between [3H]thymidine labelling index ([3H]dT LI), flow cytometric S phase cell fraction (FCM-S) and Ki-67 immunoreactivity (Ki-67/MIB-1) was verified and the type of correlation with the most important clinical, pathological and biological patient and tumour characteristics was investigated in a very large series of breast cancer patients. Ki-67/MIB-1, FCM-S and [3H]dT LI were determined in 609, 526 and 485 patients, respectively, and all three cell proliferation indices were evaluated in parallel on the same tumour in a series of 330 breast cancer patients. All the cell kinetic determinations were performed within the context of National Quality Control Programmes. Very poor correlation coefficients (ranging from 0.37 to 0.18) were observed between the different cell kinetic variables determined in parallel on the same series of breast cancers. Moreover, Ki-67/MIB-1 and FCM-S showed a significant relationship with histological type, grade and tumour size, whereas statistically significant correlations were not observed for [3H]dT LI. In conclusion, the results show that the different cell kinetic variables provide different biological information and cannot be considered as alternatives to each other.
Collapse
Affiliation(s)
- F Barzanti
- Istituto Oncologico Romagnolo, Forlì, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Caselli M, Marchisio M, Gaudio M, Saragoni L, Lanza G, Alvisi V, Bertagnolo V, Concu M, Capitani S, Caramelli E. Fhit protein expression in human gastric cancer and related precancerous lesions. Oncol Rep 2001; 8:1233-7. [PMID: 11605039 DOI: 10.3892/or.8.6.1233] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The FHIT gene is altered in several types of tumors and abnormal expression of Fhit protein have also been reported in some preneoplastic lesions. We have determined the Fhit expression on histological samples of 26 patients affected by preneoplastic lesions who developed a gastric cancer within 2 years. The expression of the Fhit protein was always present in all preneoplastic lesions, while the Fhit protein immunostaining was distributed unevenly in 10 cases and completely lost in 6. The complete loss of Fhit expression only in areas of neoplastic low differentiation suggests that FHIT gene takes part in late gastric carcinogenesis.
Collapse
Affiliation(s)
- M Caselli
- Institute of Internal Medicine I, University of Ferrara, Ferrara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Folli S, Morgagni P, Roviello F, De Manzoni G, Marrelli D, Saragoni L, Di Leo A, Gaudio M, Nanni O, Carli A, Cordiano C, Dell'Amore D, Vio A. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 2001; 31:495-9. [PMID: 11696619 DOI: 10.1093/jjco/hye107] [Citation(s) in RCA: 120] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Lymph node metastases are present in only about 15% of patients with early gastric cancer (EGC) and for this reason, the majority of these patients do not require lymphadenectomy. In Japan, EGC patients undergo less invasive treatment (endoscopic mucosal resection, wedge resection, laparoscopy). However, the indications for and results of these types of treatment are still uncertain. METHODS In a multicentre retrospective study, we analysed the clinicopathological data referring to 584 early gastric cancer patients who underwent D2 gastrectomy. A comparison was made between patients with and without lymph node metastases in relation to numerous pre- and postoperative variables. Long-term survival and risk factors for lymph node metastases were analysed. The primary aim was to compare our results with those of Western and Japanese authors; we also evaluated the possibility of identifying a subset of patients at low risk of lymph node metastases who may be candidates for endoscopic treatment. RESULTS The incidence of lymph node metastasis was 14.4%. Univariate and multivariate analyses showed that submucosal infiltration, diffuse histotype, tumour size and Kodama Pen A type were all related to the presence of lymph node metastases. Patients with types I, IIa and IIb mucosal tumours did not present lymph node metastases. Postoperative mortality was 2.2%. Five-year survival in relation to lymph node groups was 95% in N0 patients, 77% in N1 patients and 60% in N2 patients (p = 0.0001, Japanese N-stage). The number of positive lymph nodes also had a prognostic value. Patients with three or fewer positive lymph nodes presented a better 5-year prognosis (83%) than those with more than three positive lymph nodes (48%) (p = 0.0001). CONCLUSIONS Our study confirms that lymph node involvement is an extremely important prognostic factor. For this reason, the therapeutic strategy of our surgical units is as follows: 1) D2 gastrectomy is the standard treatment even in early gastric cancer (EGC); 2) endoscopic mucosal resection (EMR) could be considered first in types I, IIa and IIb tumours that are diagnosed as limited to the mucosal layer.
Collapse
Affiliation(s)
- S Folli
- U. O. di Chirurgia Toracica, Ospedale G. B. Morgagni, Forlì, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Morgagni P, Saragoni L, Folli S, Gaudio M, Scarpi E, Bazzocchi F, Marra GA, Vio A. Lymph node micrometastases in patients with early gastric cancer: experience with 139 patients. Ann Surg Oncol 2001. [PMID: 11258783 DOI: 10.1245/aso.2001.8.2.170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Although lymph node metastases in patients with early gastric cancer (EGC) is an important prognostic factor, the prognostic relevance of lymph node micrometastases is still uncertain. METHODS The authors studied 1488 lymph nodes, which were histologically confirmed as pN0, dissected from 139 patients who were treated for EGC between 1976-1994. Micrometastases were defined as a single or small cluster of neoplastic cells identifiable only by immunohistochemical methods. RESULTS Lymph node micrometastases was observed in 24 of the 139 patients (17%). No significant correlation was observed between micrometastases and other clinicopathological characteristics. Analysis of overall survival showed no significant difference between the micrometastases positive and negative groups. CONCLUSION The results of our study show that the presence of lymph node micrometastases in EGC does not have an influence on patient prognosis.
Collapse
Affiliation(s)
- P Morgagni
- 1' Department of General Surgery, Morgagni Hospital, Forlì, Italy
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Morgagni P, Saragoni L, Folli S, Gaudio M, Scarpi E, Bazzocchi F, Marra GA, Vio A. Lymph node micrometastases in patients with early gastric cancer: experience with 139 patients. Ann Surg Oncol 2001; 8:170-4. [PMID: 11258783 DOI: 10.1007/s10434-001-0170-x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND Although lymph node metastases in patients with early gastric cancer (EGC) is an important prognostic factor, the prognostic relevance of lymph node micrometastases is still uncertain. METHODS The authors studied 1488 lymph nodes, which were histologically confirmed as pN0, dissected from 139 patients who were treated for EGC between 1976-1994. Micrometastases were defined as a single or small cluster of neoplastic cells identifiable only by immunohistochemical methods. RESULTS Lymph node micrometastases was observed in 24 of the 139 patients (17%). No significant correlation was observed between micrometastases and other clinicopathological characteristics. Analysis of overall survival showed no significant difference between the micrometastases positive and negative groups. CONCLUSION The results of our study show that the presence of lymph node micrometastases in EGC does not have an influence on patient prognosis.
Collapse
Affiliation(s)
- P Morgagni
- 1' Department of General Surgery, Morgagni Hospital, Forlì, Italy
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Saragoni L, Gaudio M, Morgagni P, Folli S, Vio A, Scarpi E, Saragoni A. The role of growth patterns, according to Kodama's classification, and lymph node status, as important prognostic factors in early gastric cancer: analysis of 412 cases. Gastric Cancer 2000; 3:134-140. [PMID: 11984726 DOI: 10.1007/pl00011707] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND: During the 1970s, a special type of Gastric Cancer with excellent prognosis (early gastric cancer; EGC) was identified by the Japanese Research Society for Gastric Cancer. EGC has been defined as a tumor which invades the mucosa and/or submucosa, regardless of the lymph node status. Using this definition, we identified an initial phase of tumor development which could be treated both endoscopically and surgically.METHODS: We examined 412 EGC patients, recruited between 1976 and 1999, with an average follow-up of 9 years. All tumors were classified according to the macroscopic and microscopic criteria proposed by the Japanese Society of Gastroenterological Endoscopy (JSGE) and Lauren, respectively. The infiltrative growth pattern was evaluated according to Kodama's classification. Only tumor-related death was considered as an end-point of interest for the survival analysis.RESULTS: Submucosal tumors ( P = 0.008), Pen A (see definition below) type disease ( P = 0.0001), and lymph node-positive cancers ( P = 0.0002) were significant prognostic factors on univariate analysis. Moreover, bivariate analysis showed that the worst prognosis, in terms of survival, was for patients with nodal involvment, submucosal invasion, and node-positive and Pen-A type cancer. The abbreviation Pen, penetrating, indicates a lesion with a diameter of less than 4 cm, which invades the submucosa diffusely. Pen A type EGC represents a subgroup of tumors which infiltrates the submucosa extensively, with nodular masses, causing the complete destruction of the muscularis mucosae.CONCLUSION: In our series, Pen A type was an important prognostic factor (hazard ratio; HR, 8.32; 95% confidence interval [CI], 3.49-19.86. For this reason, we believe it is important to evaluate the infiltration into the wall in all patients with EGC, paying particular attention to the growth pattern of the neoplasm. Moreover, submucosal Pen A type tumors had a considerably worse prognosis and this finding was reinforced when lymph node metastases coexisted. We suggest, therefore, that surgical treatment with at least a D2 lymphadenectomy is performed in all these patients, as the lesions must be considered to be advanced, no longer being EGC.
Collapse
Affiliation(s)
- Luca Saragoni
- Department of Pathology, G.B. Morgagni-L. Pierantoni hospital, Vecchiazzano (Forlì), Via Forlanini 34, 47100 Forlì, Italy
| | | | | | | | | | | | | |
Collapse
|
26
|
Saragoni L, Gaudio M, Morgagni P, Folli S, Bazzocchi F, Scarpi E, Saragoni A. Identification of occult micrometastases in patients with early gastric cancer using anti-cytokeratin monoclonal antibodies. Oncol Rep 2000; 7:535-9. [PMID: 10767364 DOI: 10.3892/or.7.3.535] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The presence of occult micrometastases was evaluated in 1488 lymph nodes removed from 139 patients with node-negative early gastric cancer (EGC). Additional multiple levels of the lymph nodes were examined with haematoxylin-eosin staining and keratin immunostaining. Occult nodal micrometastases were detected in 24 patients (17%) in one or more lymph nodes dissected after a gastrectomy. The cases investigated were a small group from a total of 412 EGC patients who underwent surgical treatment in our hospital between 1976 and 1997; the mean follow-up period was 9 years (range 1-22). We found no significant differences between cytokeratin-negative and positive patients regarding the following clinicopathological parameters: age, gender, tumour size and site, macroscopic and microscopic type, depth of invasion and type of infiltration, according to Kodama's classification. The survival rate at 5 years was 88% and 87% for cytokeratin-negative and positive patients, respectively (log-rank = 0.6; ns). Our data suggest that occult micrometastases do not add useful information and immunohistochemical studies to detect them are probably unnecessary.
Collapse
Affiliation(s)
- L Saragoni
- Department of Pathology, Hospital L. Pierantoni, Vecchiazzano, Forli 47100, Italy
| | | | | | | | | | | | | |
Collapse
|
27
|
Saragoni L, Gaudio M, Vio A, Folli S, Nanni O, Saragoni A. Early gastric cancer in the province of Forlì: follow-up of 337 patients in a high risk region for gastric cancer. Oncol Rep 1998; 5:945-8. [PMID: 9625852 DOI: 10.3892/or.5.4.945] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Long-term clinical outcome was analysed in a series of 337 patients with early gastric cancer (EGC) at a median follow-up of 8 years. Tumours were classified according to the macroscopic and microscopic criteria proposed by the Japanese society of gastroenterological endoscopy (JSGE) and Lauren, respectively. Type of penetration (PEN) was classified according to Kodama. Overall survival rate was 92% at 5 years and 88% at 8 years and was significantly related to depth, type of penetration, lymph node status and tumour size. A significantly lower 5-year survival (p<0.05) was observed for patients with lymph node metastases and PEN A type EGC (55%) or for those with node-positive tumours and submucosal wall penetration (58%) than for the other pathologic subgroups. Therefore, these two subgroups should be considered as advanced gastric cancer patients from the prognostic point of view. Moreover, multivariate analysis by Cox regression model showed the degree of lymph node involvement and Kodama's type PEN A as the only independent prognostic factors.
Collapse
Affiliation(s)
- L Saragoni
- Department of Pathology,'Morgagni-Pierantoni' Hospital, Forlì 47100, Italy
| | | | | | | | | | | |
Collapse
|
28
|
Caselli M, Gaudio M, Chiamenti CM, Trevisani L, Sartori S, Saragoni L, Boldrini P, Dentale A, Ruina M, Alvisi V. Histologic findings and Helicobacter pylori in duodenal biopsies. J Clin Gastroenterol 1998; 26:74-80. [PMID: 9492870 DOI: 10.1097/00004836-199801000-00020] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We have studied the morphologic aspects of the duodenal bulb in relation to Helicobacter pylori infection in a large group of patients with endoscopically assessed duodenitis to learn more about the pathogenesis of nonspecific duodenitis (bulbitis) and to clarify the specific role of H. pylori. Eight duodenal biopsy specimens in the four quadrants of the first part of the bulb and four gastric antral biopsy specimens were taken in 208 patients. Specimens were fixed in formalin, or in glutaraldehyde, then slides were stained with hematoxylin and eosin, periodic acid-Schiff, and Alcian-Giemsa, and with toluidine blue for semithin sections. Duodenal histology revealed inflammation in 155 (74.5%) and H. pylori-like bacterial bodies in 153 (73.5%) of the patients; H. pylori infection in the gastric antrum was diagnosed in 173 (83.1%) of the patients. Distinguishing histologic aspects appeared to be related to the presence of H. pylori infection. We believe that the present histologic grading of duodenitis correlates better with the natural history of H. pylori infection in the duodenal bulb, and better fits the requirements of a modern classification than the classification commonly used in duodenitis. We conclude that the term H. pylori-linked bulbitis should be adopted as the proper term to identify the particular kind of duodenitis predisposing to peptic ulcer.
Collapse
Affiliation(s)
- M Caselli
- School of Gastroenterology, University of Ferrara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, Pellegata NS, Gaudio M, Magni E, Ranzani GN. Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. Cancer 1997. [PMID: 9010095 DOI: 10.1002/(sici)1097-0142(19970115)79:2<226::aid-cncr5>3.0.co;2-i] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The differences in survival of gastric carcinoma patients who have identical clinical or pathologic stages prompted the authors to investigate the prognostic significance of biologic features that are known to affect the clinical aggressiveness of other tumor types. METHODS One hundred twenty-four tumor samples from patients who had received radical or palliative surgery were analyzed for c-myc, c-K-ras, hst, and c-erb B-2 gene amplification by means of the Southern blot technique. Of these tumors, 70 were also examined for cell kinetics by means of the thymidine labeling index (TLI). RESULTS The analysis of associations between gene amplification and the anatomicopathologic variables (TNM classification, site of tumor, and histology) showed that amplification represents a late event in the natural history of gastric carcinoma. Gene amplification showed a slight, statistically insignificant, negative impact on overall survival (OS) (P = 0.09). Amplification of c-erb B-2 correlated in a statistically significant way with reduced OS (P = 0.03). Cox multiple regression analysis revealed that neither c-erb B-2 amplification nor TLI had prognostic significance in relation to OS. CONCLUSIONS These data indicate that amplification of the examined oncogenes did not reveal a new independent prognostic factor for patients with gastric carcinoma. However, the authors' results did show a strong correlation between gene amplification and tumor progression, which warrants further study involving larger series of patients. At the same time, the TLI results underlined the need to identify the most suitable biologic material for use in the estimation of proliferative indexes in gastric carcinoma.
Collapse
Affiliation(s)
- D Amadori
- Department of Medical Oncology, Pierantoni Hospital, Forlì, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Amadori D, Maltoni M, Volpi A, Nanni O, Scarpi E, Renault B, Pellegata NS, Gaudio M, Magni E, Ranzani GN. Gene amplification and proliferative kinetics in relation to prognosis of patients with gastric carcinoma. Cancer 1997; 79:226-32. [PMID: 9010095 DOI: 10.1002/(sici)1097-0142(19970115)79:2<226::aid-cncr5>3.0.co;2-i] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND The differences in survival of gastric carcinoma patients who have identical clinical or pathologic stages prompted the authors to investigate the prognostic significance of biologic features that are known to affect the clinical aggressiveness of other tumor types. METHODS One hundred twenty-four tumor samples from patients who had received radical or palliative surgery were analyzed for c-myc, c-K-ras, hst, and c-erb B-2 gene amplification by means of the Southern blot technique. Of these tumors, 70 were also examined for cell kinetics by means of the thymidine labeling index (TLI). RESULTS The analysis of associations between gene amplification and the anatomicopathologic variables (TNM classification, site of tumor, and histology) showed that amplification represents a late event in the natural history of gastric carcinoma. Gene amplification showed a slight, statistically insignificant, negative impact on overall survival (OS) (P = 0.09). Amplification of c-erb B-2 correlated in a statistically significant way with reduced OS (P = 0.03). Cox multiple regression analysis revealed that neither c-erb B-2 amplification nor TLI had prognostic significance in relation to OS. CONCLUSIONS These data indicate that amplification of the examined oncogenes did not reveal a new independent prognostic factor for patients with gastric carcinoma. However, the authors' results did show a strong correlation between gene amplification and tumor progression, which warrants further study involving larger series of patients. At the same time, the TLI results underlined the need to identify the most suitable biologic material for use in the estimation of proliferative indexes in gastric carcinoma.
Collapse
Affiliation(s)
- D Amadori
- Department of Medical Oncology, Pierantoni Hospital, Forlì, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
A retrospective study of 223 patients treated for early gastric cancer (EGC) is reported, representing 21.2 per cent of the 1051 patients with gastric cancer treated over the same period. Two main types of surgical procedure were used: subtotal resection of the stomach for EGC of the two lower thirds and total gastrectomy for lesions of the upper third. A lymphadenectomy of groups 1 and 2, according to the procedure of the Japanese Research Society for Gastric Cancer (R2 resection), was performed in all patients. The mean duration of follow-up was 7.5 years. Univariate analysis showed a significant difference in survival rates only between patients with and without involved nodes (log rank = 6.05, P = 0.0139). Other prognostic factors were not identified. A bivariate analysis was performed to evaluate the joint effect of node status and the Kodama classification: survival rates for patients with EGC of the penetrating (Pen) A type and node positive falls to around 57 per cent within 6 years. This group of patients has a tumour that should probably be considered as a 'non-early' lesion. To improve the survival of patients with a Pen A, node positive lesion, adjuvant chemotherapy may be appropriate.
Collapse
Affiliation(s)
- S Folli
- Department of General and Thoracic Surgery, G.B. Morgagni Hospital, Forlì, Italy
| | | | | | | | | | | | | |
Collapse
|
32
|
Cangelosi MM, Gaudio M, Brancati AM, Leggio F. Blood lipid changes in hypertensive, dyslipidemic patients under long term quinapril treatment. INT ANGIOL 1994; 13:65-7. [PMID: 8077801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVE The present study aimed at verifying Quinapril effects on both pressure and lipid profile in 15 patients (5 M, 10 F), aged 45 to 80 years (63 +/- 9), complaining for mild to moderate hypertension and dyslipidemia (total cholesterol > 200 mg/dl and triglycerides > 200 mg/dl). No relevant associated disease was present, including diabetes mellitus not any lipid lowering drugs were given. METHOD After a wash-out period of one week, all patients, who had been hypertensive for 2 to 120 months (33 +/- 11), were given Quinapril 20 mg orally once a day for 6 months and kept on a low lipid diet from before treatment to the end of the study. Lipid profile we assessed at three-month intervals. RESULTS Blood pressure, monitored at two-week intervals, significantly decreased on the 1st month (p < 0.001), and kept lower thereafter. Mean total cholesterol, triglycerides and low density lipoprotein cholesterol levels, after 6 months of therapy, were reduced by 44 mg/dl (p < 0.001), 29 mg/dl (p < 0.001) and 39 mg/dl (p < 0.002) respectively. CONCLUSIONS Our results seen indicate that Quinapril antihypertensive effects are accompanied by a significant improvement of the lipid profile.
Collapse
Affiliation(s)
- M M Cangelosi
- Unità Operativa Cardiologica, INRCA, National Institute of Research, Rome, Italy
| | | | | | | |
Collapse
|
33
|
Saponaro A, Martinez R, Gaudio M, Dragagna G, Marotta P, Leggio F, Cangelosi MM. [Cutaneous microcirculation and diabetic disease. A functional and flowmetry study in subjects with diabetes mellitus type 2]. Cardiologia 1993; 38:317-21. [PMID: 8402741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Laser-Doppler single fingertip skin blood flow has been evaluated in 41 euglycemic type II diabetic patients under basal conditions and after dynamic testing (both ischemia and thermal stress). The same subjects have also undergone tests for the assessment of the degree of autonomic nervous system (ANS) dysfunction. The results have been compared to those obtained in 38 age-matched healthy subjects. In diabetic patients: baseline flow levels were much higher; the post-ischemic flow increase was less evident; a shorter hyperemic phase followed ischemia; a longer latency period was noticed, during thermal stress, together with a lower and slower hyperemic peak level. According to the results of ANS dynamic tests, diabetic subjects were divided into 3 groups: Group 1 (subjects with negative results); Group 2 (subjects with only one positive result); Group 3 (subjects with more than one positive test). Microcirculation disturbances were more often found in Group 3. These results show that a correlation exists between diabetic microangiopathy and ANS dysfunction. They also support the hypothesis, already pointed out by other research groups, of a similar mechanism causing diabetic neurologic and vascular complications.
Collapse
Affiliation(s)
- A Saponaro
- II Cattedra di Semeiotica Cardiovascolare, Università degli Studi La Sapienza, Roma
| | | | | | | | | | | | | |
Collapse
|
34
|
Xu SG, Zotz RB, Recklinghausen GV, Meusers P, Goebell H, Khandekar MAK, Lesseis AM, Eastwood MA, Palmer KR, Rizzi C, Avellini C, Scott CA, Floretti G, Desinan L, Beltrami CA, Igarashi H, Takahashi S, Ishiyama N, Nakamura K, Masubuchi N, Saito S, Aoyagi T, Itoh T, Hirata I, Miglio F, Miglioli M, Mazzeo V, Holton J, Mulè P, Menegatti M, Maiolo P, Grazia E, Bini A, Gusmaroli R, Casadei A, Valpiani D, Gaudio M, Bazzocchi R, Barbara L, Webb P, Forman D, Ierardi E, Monno RA, Ingrosso M, Panza P, Lorenzis AD, Rizzi S, Pisani A, Valenza M, Francavilla A, Fukuda Y, Inoue H, Yamamoto I, Tonokatsu Y, Tamura T, Hori S, Shimoyama T, Little CL, Corbett-Feeney G, O’Callaghan J, McCarthy CF, Testoni PA, Colombo E, Bagnolo F, Jonghi-Lavarini E, Scelsi R, Fiocca R, Farinati F, Valiante F, Delia Libera G, Germanà B, Baffa R, Rugge M, Vianello F, Mario FD, Fox JG, Blanco M, Murphy JC, Kabok Z, Pappo J. Gastric cancer. Ir J Med Sci 1992. [DOI: 10.1007/bf02942892] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Cangelosi MM, Leggio F, Gaudio M, Strollo G, Martinez MR, Saponaro A. [The incidence and clinical significance of the echocardiographic finding of false chordae tendineae]. Ann Ital Med Int 1992; 7:102-5. [PMID: 1467123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The presence of false tendons (FT) with M-mode and 2-D echocardiography in a consecutive series of 916 patients (520 men--396 women) with a wide age range (9-83 y) was investigated, and a possible correlation with heart systolic murmurs and/or heart arrhythmias evaluated. The problems that FT cause in differential diagnosis with other intraventricular structures were also considered. FT were observed in 53 subjects (5.8%), 30 men--23 women, and in an additional 51 cases (96%) in the left ventricular cavity. A clear prevalence of FT was observed during childhood and adolescence (26.1%), with the preferential location at the top of the ventricular chamber. No relevant correlation between FT and heart systolic murmurs and/or cardiac rhythm disorders was found. Although our results show that FT constitute an occasional finding, with no anatomic or functional relevance, they should always be held in due consideration in case of diagnostic uncertainty with other pathological structures, in particular intracavitary thrombi.
Collapse
Affiliation(s)
- M M Cangelosi
- Unità Operativa Cardiologica INRCA, Istituto a carattere scientifico, sede di Roma
| | | | | | | | | | | |
Collapse
|
36
|
Saragoni A, Medri L, Bacci F, Padovani F, Sabattini E, Nanni O, Gaudio M. [Value of the in situ hybridization technique in the diagnosis of human papilloma virus infections of the uterine cervix. Correlations between the human papilloma virus type and the morphological features]. Pathologica 1992; 84:57-66. [PMID: 1323097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Clinico-pathologic, epidemiologic and molecular analytic studies have shown that: i) the squamous cancer of the uterine cervix derives from intraepithelial lesions with different degrees of atypia; ii) human papillomavirus (HPV) can play a fundamental role in the progression of these lesions. We have examined 219 uterine cervix biopsies by means of the in situ hybridization technique (ISH) using biotinylated probes for 6/11, 16/18 and 31/35/51 HPV strains. The histologic lesions were as follows: 104 (49.7%) focal koilocytotic lesions 26 (11.8%) low grade intraepithelial lesions (SIL) 45 (20.5%) high grade intraepithelial lesions (SIL) 18 (8.2%) condylomata acuminata 21 (9.8%) invasive cancers. The percentage of the positivity found in the whole material examined is 14.1%. In particular, none of the 109 cases of focal koilocytotic lesions was positive, whereas the 28.1% of the remaining 110 biopsies turned out to contain HPV. We hypothesize that our small percentage of positivity in preinvasive and invasive lesions of the uterine cervix can be due to the fact that the HPV is not the only cancerogenic factor involved, although the possibility of a low sensitivity of the technique cannot completely be excluded.
Collapse
Affiliation(s)
- A Saragoni
- Servizio di anatomia patologica, Ospedale Morgagni-Pierantoni, Forlì
| | | | | | | | | | | | | |
Collapse
|
37
|
Saragoni A, Falini B, Medri L, Gaudio M, Brizio R, Poggi S, Sabattini E, Pileri S. [Peripheral T-cell lymphoma associated with hemophagocytic syndrome: a recently identified entity. Clinico-pathologic and immunohistochemical study of 2 cases]. Pathologica 1990; 82:359-69. [PMID: 2284138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The authors report on two examples of peripheral T-cell lymphoma associated with hemophagocytic syndrome. The latter represents a recently described entity, which is characterized by pancytopenia, hepatosplenomegaly, fever and rapid downhill clinical course. Microscopic examination of different tissue samples shows bone-marrow, liver and spleen infiltration by small-medium sized lymphoid elements, which display peripheral T-cell phenotype and are associated with an exuberant hyperplasia of hemophagocytosing, benign-looking histiocytes. The clinical and pathological findings, along with the main differential diagnoses, are discussed.
Collapse
Affiliation(s)
- A Saragoni
- Servizio di anatomia e istologia patologica, Ospedale Morgagni-Pierantoni di Forlì
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Gaudio M, Brizio R, Medri L, Marra GA, Padovani F, Vio A, Saragoni A. [Epidermoid cyst of the spleen. Presentation of a case]. Pathologica 1990; 82:465-70. [PMID: 2284149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Cystic lesions of the spleen are unusual. They are classified essentially as: parasitic or nonparasitic, based on their etiology, and true or pseudo based on the presence or absence of lining epithelium. The pathogenesis of true cysts is unknown and numerous hypotheses are given by different Authors. After a short review of the literature, the Authors describe the clinical and pathological data of a case of epithelial (epidermoid) splenic cyst occurs in a 12-year-old woman. The Authors put forward some personal observations on pathogenesis, still doubtful, by means of histochemical and immunohistochemical study.
Collapse
Affiliation(s)
- M Gaudio
- Servizio di anatomia ed istologia patologica, Ospedale G.B. Morgagni-L. Pierantoni di Forlì
| | | | | | | | | | | | | |
Collapse
|
39
|
Ricca Rosellini S, Grilli F, Gaudio M, Saragoni A, Miglio F. Hepatic injury associated with amineptine therapy. Ital J Gastroenterol 1990; 22:40-3. [PMID: 2131927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Cases are reported of two patients in whom acute hepatitis and cholestatic jaundice were induced by a tricyclic antidepressant, amineptine. A 29-year old woman received amineptine for 10 days before the onset of acute hepatitis. Slight jaundice and pruritus were preceded by fever, nausea and anorexia. The case is documented by a rapid return to normality of the liver function tests after amineptine was discontinued. We also report the case of a 55-year old woman to whom amineptine was administered for 4 weeks: she was admitted to our Department due to a 14-day history of pruritus and painless jaundice. Histological examination, in this case showed marked cholestasis without inflammatory infiltration. After suspending the treatment, it took 3 weeks for the liver function tests to return to normal. These observations, and the features of the cases published in the literature, suggest that amineptine can produce a wide spectrum of liver injuries, in different patients, taking the form of hepatocellular necrosis, cholestasis or a combination of both.
Collapse
Affiliation(s)
- S Ricca Rosellini
- Divisione di Medicina Generale e Gastroenterologia, Ospedale G. B. Morgagni- L. Pierantoni, Forlì, Italy
| | | | | | | | | |
Collapse
|
40
|
|
41
|
Agosti R, De Giorgio R, Gaudio M, Paparo GF, Stanghellini V, Saragoni A, Corinaldesi R. Isolated metastasis to the gallbladder of a malignant melanoma of the skin. Report of a case. Pathologica 1989; 81:333-8. [PMID: 2641546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
A case of single, polypoid metastatic malignant melanoma of the gallbladder is described. The differential diagnosis with primary malignant melanoma and undifferentiated carcinoma is discussed.
Collapse
|
42
|
Grigioni WF, D'Errico A, Bacci F, Gaudio M, Mazziotti A, Gozzetti G, Mancini AM. Primary liver neoplasms: evaluation of proliferative index using MoAb Ki67. J Pathol 1989; 158:23-9. [PMID: 2547043 DOI: 10.1002/path.1711580107] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Thirty-two cases of primary liver neoplasms comprising 12 benign, 15 malignant, and 5 cases with equivocal histopathological features between benign and malignant have been investigated using monoclonal antibody (MoAb) Ki67, which reacts with a nuclear protein expressed in the G1, G2, S, and M phases of the cell cycle. The Ki67 score (positive cells/total neoplastic cells) seems to correlate to the classes of lesions tested. In the hepatocellular carcinoma (HCC) group, the percentage of labelled nuclei, ranging from 15 to 50 per cent, showed a good correlation with Edmondson-Steiner's histological tumour grade. A percentage of positive cells similar to that of the proved low-grade HCCs was detected in the five neoplastic lesions in which the routine histopathological criteria of malignancy were not fulfilled. The benign neoplasms showed a very low growth fraction, similar to that of normal or cirrhotic tissues. The use of the Ki67 score seems to offer useful information about the biological behaviour of some liver masses and may help in the differential diagnosis of hepatocellular adenoma versus carcinoma.
Collapse
Affiliation(s)
- W F Grigioni
- Department of Pathology, Bologna University, Italy
| | | | | | | | | | | | | |
Collapse
|
43
|
Cangelosi MM, Russo R, Van Dyke A, Gaudio M, Giordano M. [False chordae tendineae: incidence and clinical meaning]. Minerva Cardioangiol 1989; 37:51-4. [PMID: 2725908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The presence of false tendons (FT) was sought with M-mode and 2-D echocardiography in a consecutive series of 316 patients with a wide age range (13-73 yrs). FT were observed in 13 patients (4.1%), all of them in the left ventricular cavity. Their clinical significance is pointed out together with the possibility of diagnostic error with other pathological formations, particularly intracavitary thrombi.
Collapse
|